clinical trial · NCT05050097
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Janssen Research & Development, LLC·phase1·active not recruiting·n = 166
Multiple MyelomaTalquetamabCarfilzomibDaratumumab SCLenalidomidePomalidomide
brief summary
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
started
Sep 22, 2021
primary completion
Mar 31, 2025
completion
Apr 7, 2027
last updated
Jul 6, 2026
official title
A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol